Corrigendum to: Oligodendrocytes modulate the immune-inflammatory response in EAE via TNFR2 signaling (Brain Behavior and Immunity (2020) 84 (132–146), (S0889159119307962), (10.1016/j.bbi.2019.11.017))

Pernille M. Madsen, Haritha L. Desu, Juan Pablo de Rivero Vaccari, Yoleinny Florimon, Ditte G. Ellman, Robert W. Keane, Bettina H. Clausen, Kate L. Lambertsen, Roberta Brambilla

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret <the omission of the following Conflict of Interest statement: JPdRV and RWK are co-founders and managing members of InflamaCORE, LLC. RB, JPdRV, and RWK have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV and RWK are Scientific Advisory Board Members of ZyVersa Therapeutics.>

Original languageEnglish (US)
JournalBrain, Behavior, and Immunity
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Fingerprint

Dive into the research topics of 'Corrigendum to: Oligodendrocytes modulate the immune-inflammatory response in EAE via TNFR2 signaling (Brain Behavior and Immunity (2020) 84 (132–146), (S0889159119307962), (10.1016/j.bbi.2019.11.017))'. Together they form a unique fingerprint.

Cite this